Immuto Scientific Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$8M
- Investors
-
12
Immuto Scientific General Information
Description
Developer of an artificial intelligence-enabled drug discovery platform designed to identify disease-specific protein targets and develop antibody therapeutics. The company's platform combines structural surfaceomics, cell-surface protein analysis in living disease-relevant systems, artificial intelligence-based target prioritization, conformational modeling, and antibody optimization for affinity and developability, enabling biopharmaceutical companies and research organizations to identify previously undetected therapeutic targets and develop biologic treatments, particularly for oncology.
Contact Information
Website
www.immutoscientific.comCorporate Office
- 1 Broadway
- Cambridge, MA 02142
- United States
Corporate Office
- 1 Broadway
- Cambridge, MA 02142
- United States
Immuto Scientific Timeline
Immuto Scientific Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Seed Round | 18-Sep-2025 | $8M | Completed | Pre-Clinical Trials | ||
| 7. Grant | 30-Aug-2024 | Completed | Pre-Clinical Trials | |||
| 6. Grant | 10-Aug-2022 | Completed | Pre-Clinical Trials | |||
| 5. Seed Round | 08-Oct-2021 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | 23-Apr-2019 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | 01-Sep-2018 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 16-Dec-2017 | Completed | Pre-Clinical Trials | |||
| 1. Accelerator/Incubator | Completed | Startup |
Immuto Scientific Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Immuto Scientific Comparisons
Industry
Financing
Details
Immuto Scientific Competitors (5)
One of Immuto Scientific’s 5 competitors is BigHat Biosciences, a Venture Capital-Backed company based in San Mateo, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BigHat Biosciences | Venture Capital-Backed | San Mateo, CA | ||||
| DISCO Pharmaceuticals | Venture Capital-Backed | Cologne, Germany | ||||
| Generate Biomedicines | Formerly VC-backed | Somerville, MA | ||||
| InduPro | Venture Capital-Backed | Seattle, WA | ||||
| A-Alpha Bio | Venture Capital-Backed | Seattle, WA |
Immuto Scientific Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Immuto Scientific Patents
Immuto Scientific Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4774283-A1 | Compositions and methods for plasma-free trifluoromethyl and hydroxyl radical labeling | Pending | 06-Sep-2023 | ||
| US-20250076308-A1 | Compositions and methods for plasma-free trifluoromethyl and hydroxyl radical labeling | Pending | 06-Sep-2023 | ||
| WO-2025054387-A1 | Compositions and methods for plasma-free trifluoromethyl and hydroxyl radical labeling | Inactive | 06-Sep-2023 | ||
| US-20250076297-A1 | Compositions and methods for plimb-mediated radical labeling in vivo | Pending | 06-Sep-2023 | ||
| US-20240400609-A1 | Compositions and methods for multiplexed plimb-mediated radical labeling | Pending | 02-Jun-2023 | G01N33/58 |
Immuto Scientific Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Immuto Scientific Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| DYDX | Venture Capital | Minority | ||
| Gravity Fund | Venture Capital | Minority | ||
| XPonential Ventures | Venture Capital | Minority | ||
| Wisconsin Economic Development | Government | |||
| National Institute of General Medical Sciences | Government |
Immuto Scientific FAQs
-
When was Immuto Scientific founded?
Immuto Scientific was founded in 2017.
-
Where is Immuto Scientific headquartered?
Immuto Scientific is headquartered in Cambridge, MA.
-
What is the size of Immuto Scientific?
Immuto Scientific has 16 total employees.
-
What industry is Immuto Scientific in?
Immuto Scientific’s primary industry is Biotechnology.
-
Is Immuto Scientific a private or public company?
Immuto Scientific is a Private company.
-
What is Immuto Scientific’s current revenue?
The current revenue for Immuto Scientific is .
-
How much funding has Immuto Scientific raised over time?
Immuto Scientific has raised $10.4M.
-
Who are Immuto Scientific’s investors?
DYDX, Gravity Fund, XPonential Ventures, Wisconsin Economic Development, and National Institute of General Medical Sciences are 5 of 12 investors who have invested in Immuto Scientific.
-
Who are Immuto Scientific’s competitors?
BigHat Biosciences, DISCO Pharmaceuticals, Generate Biomedicines, InduPro, and A-Alpha Bio are competitors of Immuto Scientific.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
